Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/10/2019
SIETES contiene 92826 citas

 
 
<< anterior 21 a 40 de 231 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Griffin MR. High-dose non-steroidal anti-inflammatories: painful choices. Lancet 2013;382:746-8. [Ref.ID 95994]
22. Cita con resumen
Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, De Ponti F. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013;36:467-79. [Ref.ID 95666]
23. Cita con resumen
Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ. Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc 2013;88:315-25. [Ref.ID 95349]
24. Cita con resumen
Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024-33. [Ref.ID 93760]
25.Tiene citas relacionadas
Ray WA, Murray KT, Stein CM. Azithromycin and the risk of cardiovascular death. Author/editor response. N Engl J Med 2012;367:775. [Ref.ID 93628]
26.Tiene citas relacionadas
dos Santos RP, Kuchenbecker R. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;367:774. [Ref.ID 93627]
27.Tiene citas relacionadas
Koga T, Imaoka H. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;367:773-4. [Ref.ID 93626]
28.Tiene citas relacionadas
Louie R. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;367:773. [Ref.ID 93625]
29.Tiene citas relacionadas
Albert RK, Connett J, Woodruff PG. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;367:772. [Ref.ID 93624]
30.Tiene citas relacionadas
Knirsch CA, Chandra R. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;367:772. [Ref.ID 93623]
31. Cita con resumen
Holtzman NA. Chronicle of an unforetold death. Arch Intern Med 2012;172:1174-8. [Ref.ID 93591]
32.Tiene citas relacionadas Cita con resumen
Anónimo. Safety of azithromycin. Med Lett Drugs Ther 2012;54:45. [Ref.ID 93203]
33. Cita con resumen
Anónimo. Vandetanib: risk of fatal outcome. Canada. WHO Drug Information 2012;26:112. [Ref.ID 93056]
35.Tiene citas relacionadas Cita con resumen
Ray WA, Murray KT, Hall K, Arbogast PG, Stein M. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90. [Ref.ID 92984]
37.Tiene citas relacionadas Cita con resumen
Anónimo. Fingolimod: décès de causes cardiovasculaires. Prescrire 2012;32:198. [Ref.ID 92453]
38. Cita con resumen
39.Tiene citas relacionadas
Shaw P. ADHD medications and cardiovascular risk: some heartening news. JAMA 2011;306:2723-4. [Ref.ID 91840]
40.Tiene citas relacionadas Cita con resumen
Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham C, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011;306:2673-83. [Ref.ID 91839]
Seleccionar todas
 
<< anterior 21 a 40 de 231 siguiente >>